9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
The DOI matches its Crossref record; 90 of the 94 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the latest American Diabetes Association (ADA) [62], Italian Society of Diabetology (SID) [63] and KDIGO guidelines [64] differentiate the pharmacological approach to T2DM not just based on the target glycaemic values but also taking into account the indicators of high-risk or established atherosclerotic cardiovascular disease, CKD and heart failure.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [62]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“temshasbeensupported in the literature in adolescents and adults with type 1 diabetes (16,17), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (…”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594
Garg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585 · cited 1×
“temshasbeensupported in the literature in adolescents and adults with type 1 diabetes (16,17), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (…”
BackgroundEfficacy and safety of degludec versus glargine in type 2 diabetes.
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615692 · Cited by 574
Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study
Aroda, V. R., Edelstein, S. L., Goldberg, R. B., Knowler, W. C., Marcovina, S. M., Orchard, T. J., Bray, G. A., Schade, D. S., Temprosa, M. G., White, N. H., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3754 · Cited by 536
Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review
DeWitt, D. E., & Hirsch, I. B. (2003) · JAMA · doi:10.1001/jama.289.17.2254 · Cited by 502
Yeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
Aroda, V. R., Bain, S. C., Cariou, B., Piletič, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30085-2 · Cited by 464
Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0132-0 · Cited by 434
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434
Bell, K. J., Smart, C. E., Steil, G. M., Brand-Miller, J. C., King, B., & Wolpert, H. A. (2015) · Diabetes Care · doi:10.2337/dc15-0100 · Cited by 390
Eng, C., Kramer, C. K., Zinman, B., & Retnakaran, R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61335-0 · Cited by 383
Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzer, T. W., Plank, J., Kaiser, T., Pieber, T. R., & Siebenhofer, A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005613.pub3 · Cited by 366
Matthews, D. R., Paldánius, P. M., Proot, P., Chiang, Y., Stumvoll, M., & Del Prato, S. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32131-2 · Cited by 364 · cited 1×
“tending primary and secondary failure (48).”
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
Rosenstock, J., Marquard, J., Laffel, L. M., Neubacher, D., Kaspers, S., Cherney, D. Z., Zinman, B., Skyler, J. S., George, J., Soleymanlou, N., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1749 · Cited by 363 · cited 1×
“with insulin alone (32,33); however, SGLT2 inhibitor use in type 1 diabetes is associated with a two- to fourfold increase in ketoacidosis.”
BackgroundPetrie, J. R., Chaturvedi, N., Ford, I., Brouwers, M. C. G. J., Greenlaw, N., Tillin, T., Hramiak, I., Hughes, A. D., Jenkins, A. J., Klein, B. E. K., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30194-8 · Cited by 357
Tsapas, A., Avgerinos, I., Karagiannis, T., Malandris, K., Manolopoulos, A., Andreadis, P., Liakos, A., Matthews, D. R., & Bekiari, E. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0864 · Cited by 346
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care · doi:10.2337/dc12-1205 · Cited by 336
Henry, R. R., Murray, A. V., Marmolejo, M. H., Hennicken, D., Ptaszynska, A., & List, J. F. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02911.x · Cited by 310
Ratner, R. E., Dickey, R., Fineman, M., Maggs, D. G., Shen, L., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01319.x · Cited by 307
Bolli, G. B., Riddle, M. C., Bergenstal, R. M., Ziemen, M., Sestakauskas, K., Goyeau, H., Home, P. D., & on behalf of the EDITION 3 study investigators (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12438 · Cited by 301
Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Griffen, S. C., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., Proietto, J., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30308-x · Cited by 293
New insulin delivery recommendations
Frid, A. H., Kreugel, G., Grassi, G., Halimi, S., Hicks, D., Hirsch, L. J., Smith, M. J., Wellhoener, R., Bode, B. W., Hirsch, I. B., et al. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.06.010 · Cited by 286
Yki-Järvinen, H., Bergenstal, R., Ziemen, M., Wardecki, M., Muehlen-Bartmer, I., Boelle, E., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-0990 · Cited by 274
Giorgino, F., Benroubi, M., Sun, J.-H., Zimmermann, A. G., & Pechtner, V. (2015) · Diabetes Care · doi:10.2337/dc14-1625 · Cited by 268
Cleary, P. A., Orchard, T. J., Genuth, S., Wong, N. D., Detrano, R., Backlund, J.-Y. C., Zinman, B., Jacobson, A., Sun, W., Lachin, J. M., et al. (2006) · Diabetes · doi:10.2337/db06-0653 · Cited by 264
Insulin Access and Affordability Working Group: Conclusions and Recommendations
Cefalu, W. T., Dawes, D. E., Gavlak, G., Goldman, D., Herman, W. H., Van Nuys, K., Powers, A. C., Taylor, S. I., Yatvin, A. L., & on behalf of the Insulin Access and Affordability Working Group (2018) · Diabetes Care · doi:10.2337/dci18-0019 · Cited by 256
Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis
Singh, S. R., Ahmad, F., Lal, A., Yu, C., Bai, Z., & Bennett, H. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081041 · Cited by 243
Diamant, M., Nauck, M. A., Shaginian, R., Malone, J. K., Cleall, S., Reaney, M., de Vries, D., Hoogwerf, B. J., MacConell, L., Wolffenbuttel, B. H. R., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0876 · Cited by 228
Home, P. D., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Rojeski, M., Espinasse, M., & Riddle, M. C. (2015) · Diabetes Care · doi:10.2337/dc15-0249 · Cited by 221
Wysham, C., Bhargava, A., Chaykin, L., de la Rosa, R., Handelsman, Y., Troelsen, L. N., Kvist, K., & Norwood, P. (2017) · JAMA · doi:10.1001/jama.2017.7117 · Cited by 221
Efficacy of carbohydrate counting in type 1 diabetes: A systematic review and meta-analysis
Bell, K. J., Barclay, A. W., Petocz, P., Colagiuri, S., & Brand-Miller, J. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70144-x · Cited by 213
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes
Monami, M., Marchionni, N., & Mannucci, E. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.04.007 · Cited by 211
Abdul‐Ghani, M. A., Puckett, C., Triplitt, C., Maggs, D., Adams, J., Cersosimo, E., & DeFronzo, R. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12417 · Cited by 208
Lane, W., Bailey, T. S., Gerety, G., Gumprecht, J., Philis-Tsimikas, A., Hansen, C. T., Nielsen, T. S. S., Warren, M., Group Information, & 1, T. S. (2017) · JAMA · doi:10.1001/jama.2017.7115 · Cited by 206
Mortality in type 1 diabetes in the DCCT/EDIC versus the general population
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) · Diabetes Care · doi:10.2337/dc15-2399 · Cited by 194
The cost of diabetes care-an elephant in the room
Riddle, M. C., & Herman, W. H. (2018) · Diabetes Care · doi:10.2337/dci18-0012 · Cited by 191
Vijan, S., Sussman, J. B., Yudkin, J. S., & Hayward, R. A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2894 · Cited by 185
Blonde, L., Merilainen, M., Karwe, V., Raskin, P., & TITRATE™ Study Group (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01060.x · Cited by 180
Insulin therapy and hypoglycemia
McCall, A. L. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.001 · Cited by 177 · cited 1×
“unit/kg), and have lower rates of hypoglycemia (86).”
BackgroundRussell-Jones, D., Bode, B. W., De Block, C., Franek, E., Heller, S. R., Mathieu, C., Philis-Tsimikas, A., Rose, L., Woo, V. C., Østerskov, A. B., et al. (2017) · Diabetes Care · doi:10.2337/dc16-1771 · Cited by 177
Edelman, S., Garg, S., Frias, J., Maggs, D., Wang, Y., Zhang, B., Strobel, S., Lutz, K., & Kolterman, O. (2006) · Diabetes Care · doi:10.2337/dc06-0042 · Cited by 166
Phung, O. J., Sobieraj, D. M., Engel, S. S., & Rajpathak, S. N. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12233 · Cited by 165
Bartley, P. C., Bogoev, M., Larsen, J., & Philotheou, A. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02407.x · Cited by 159
Abd El Aziz, M. S., Kahle, M., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12804 · Cited by 155
Patel, M. R., Piette, J. D., Resnicow, K., Kowalski-Dobson, T., & Heisler, M. (2016) · Medical Care · doi:10.1097/mlr.0000000000000565 · Cited by 143
Buckingham, B. A., Raghinaru, D., Cameron, F., Bequette, B. W., Chase, H. P., Maahs, D. M., Slover, R., Wadwa, R. P., Wilson, D. M., Ly, T., et al. (2015) · Diabetes Care · doi:10.2337/dc14-3053 · Cited by 139
Dean, P. G., Kukla, A., Stegall, M. D., & Kudva, Y. C. (2017) · BMJ · doi:10.1136/bmj.j1321 · Cited by 133
Yki‐Järvinen, H., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Wardecki, M., Muehlen‐Bartmer, I., Maroccia, M., & Riddle, M. C. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12532 · Cited by 131
Maiorino, M. I., Chiodini, P., Bellastella, G., Capuano, A., Esposito, K., & Giugliano, D. (2017) · Diabetes Care · doi:10.2337/dc16-1957 · Cited by 125
Cost-related medication non-adherence among U.S. adults with diabetes
Kang, H., Lobo, J. M., Kim, S., & Sohn, M.-W. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.06.016 · Cited by 119
Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
Cahn, A., & Cefalu, W. T. (2016) · Diabetes Care · doi:10.2337/dcs15-3007 · Cited by 118
Tricco, A. C., Ashoor, H. M., Antony, J., Beyene, J., Veroniki, A. A., Isaranuwatchai, W., Harrington, A., Wilson, C., Tsouros, S., Soobiah, C., et al. (2014) · BMJ · doi:10.1136/bmj.g5459 · Cited by 117
Maloney, A., Rosenstock, J., & Fonseca, V. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1307 · Cited by 115
Bode, B. W., McGill, J. B., Lorber, D. L., Gross, J. L., Chang, P.-C., Bregman, D. B., & for the Affinity 1 Study Group (2015) · Diabetes Care · doi:10.2337/dc15-0075 · Cited by 114
Riddle, M. C., Yki‐Järvinen, H., Bolli, G. B., Ziemen, M., Muehlen‐Bartmer, I., Cissokho, S., & Home, P. D. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12472 · Cited by 110 · cited 1×
“tion of action than U-100 glargine but modestly lower efficacy per unit administered (90,91).”
BackgroundGlucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s130834 · Cited by 107
Terauchi, Y., Koyama, M., Cheng, X., Takahashi, Y., Riddle, M. C., Bolli, G. B., & Hirose, T. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12618 · Cited by 106
Singh, S., Wright, E. E., Kwan, A. Y. M., Thompson, J. C., Syed, I. A., Korol, E. E., Waser, N. A., Yu, M. B., & Juneja, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12805 · Cited by 101
Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis
Mannucci, E., Monami, M., & Marchionni, N. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00934.x · Cited by 96
Rodbard, H. W., Visco, V. E., Andersen, H., Hiort, L. C., & Shu, D. H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70090-1 · Cited by 91 · cited 1×
“Starting with a single prandial dose with the largest meal of the day is simple and effective, and it can be advanced to a regimen with multiple prandial doses if necessary (96).”
BackgroundKlaff, L., Cao, D., Dellva, M. A., Tobian, J., Miura, J., Dahl, D., Lucas, J., & Bue‐Valleskey, J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14100 · Cited by 91
Rodbard, H. W., Cariou, B., Zinman, B., Handelsman, Y., Philis‐Tsimikas, A., Skjøth, T. V., Rana, A., Mathieu, C., & The BEGIN Once Long Trial Investigators (2013) · Diabetic Medicine · doi:10.1111/dme.12303 · Cited by 89
Out, M., Kooy, A., Lehert, P., Schalkwijk, C. A., & Stehouwer, C. D. A. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.11.001 · Cited by 84
Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir
Davies, M., Heller, S., Sreenan, S., Sapin, H., Adetunji, O., Tahbaz, A., & Vora, J. (2013) · Diabetes Care · doi:10.2337/dc12-1333 · Cited by 83
Wang, W., Liu, H., Xiao, S., Liu, S., Li, X., & Yu, P. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0282-3 · Cited by 70 · cited 1×
“2%) reductions in A1C compared with insulin alone in people with type 1 diabetes and also reduced body weight by;3 kg (31).”
MethodAkturk, H. K., Snell-Bergeon, J. K., Rewers, A., Klaff, L. J., Bode, B. W., Peters, A. L., Bailey, T. S., & Garg, S. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0200 · Cited by 70
Aroda, V. R., González-Galvez, G., Grøn, R., Halladin, N., Haluzík, M., Jermendy, G., Kok, A., Őrsy, P., Sabbah, M., Sesti, G., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30184-6 · Cited by 68
The Evidence Base for Diabetes Technology: Appropriate and Inappropriate Meta-Analysis
Pickup, J. C. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700617 · Cited by 56
Meng, H., Zhang, A., Liang, Y., Hao, J., Zhang, X., & Lu, J. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2983 · Cited by 56
Bergenstal, R. M., Strock, E. S., Peremislov, D., Gibney, M. A., Parvu, V., & Hirsch, L. J. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.12.014 · Cited by 54
Porcellati, F., Lucidi, P., Cioli, P., Candeloro, P., Marinelli Andreoli, A., Marzotti, S., Ambrogi, M., Bolli, G. B., & Fanelli, C. G. (2015) · Diabetes Care · doi:10.2337/dc14-0649 · Cited by 52
Vaz, E. C., Porfírio, G. J. M., Nunes, H. R. D. C., & Nunes-Nogueira, V. D. S. (2018) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000045 · Cited by 52
Owens, D. R., Traylor, L., Mullins, P. R., & Landgraf, W. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.10.022 · Cited by 48
Dose-response effects of insulin glargine in type 2 diabetes
Wang, Z., Hedrington, M. S., Gogitidze Joy, N., Briscoe, V. J., Richardson, M. A., Younk, L., Nicholson, W., Tate, D. B., & Davis, S. N. (2010) · Diabetes Care · doi:10.2337/dc09-2011 · Cited by 44
Babu, A., Mehta, A., Guerrero, P., Chen, Z., Meyer, P. M., Koh, C. K., Roberts, R., Schaider, J., & Fogelfeld, L. (2009) · Endocrine Practice · doi:10.4158/ep09117.orr · Cited by 34 · cited 1×
“However, there is evidence that patients with uncontrolled hyperglycemia associated with type 2 diabetes can also be effectively treated with a sulfonylurea (43).”
BackgroundOverbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin
Cowart, K. (2020) · Clinical Diabetes · doi:10.2337/cd19-0061 · Cited by 33
Wysham, C., Hood, R. C., Warren, M. L., Wang, T., Morwick, T. M., & Jackson, J. A. (2016) · Endocrine Practice · doi:10.4158/ep15959.or · Cited by 29 · cited 1×
“Regular U-500 has distinct pharmacokinetics with delayed onset and longer duration of action, has characteristics more like an intermediate-acting (NPH) insulin, and can be used as two or three daily injections (89).”
BackgroundHeller, S., Bode, B., Kozlovski, P., & Svendsen, A. L. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12060 · Cited by 28
Research works printed but not linked: 3
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
Cited by
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
Trends in diabetes treatment and control in U.S. adults, 1999-2018
Fang, M., Wang, D., Coresh, J., & Selvin, E. (2021) · New England Journal of Medicine · doi:10.1056/nejmsa2032271 · Cited by 690
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Kanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.049 · Cited by 618
“78”
Nordanstig, J., Behrendt, C.-A., Baumgartner, I., Belch, J., Bäck, M., Fitridge, R., Hinchliffe, R., Lejay, A., Mills, J. L., Rother, U., et al. (2024) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2023.08.067 · Cited by 515
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-04
- Volume
- 44
- Issue
- Supplement_1
- Pages
- S111-S124
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4254445254
- Cited by
- 972
- References
- 94
- Citations by year
- 2026: 29 · 2025: 55 · 2024: 86 · 2023: 148 · 2022: 334 · 2021: 318 · 2020: 1
- FWCI
- 30.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- pharmacotherapy, diabetes management, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.